Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

NASDAQ:RXST - Nasdaq - US78349D1072 - Common Stock - Currency: USD

15.8  -0.21 (-1.31%)

Fundamental Rating

4

Taking everything into account, RXST scores 4 out of 10 in our fundamental rating. RXST was compared to 189 industry peers in the Health Care Equipment & Supplies industry. RXST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RXST shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RXST has reported negative net income.
RXST had a negative operating cash flow in the past year.
RXST had negative earnings in 4 of the past 5 years.
In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

With a decent Return On Assets value of -8.48%, RXST is doing good in the industry, outperforming 62.96% of the companies in the same industry.
RXST has a Return On Equity of -9.50%. This is in the better half of the industry: RXST outperforms 66.67% of its industry peers.
Industry RankSector Rank
ROA -8.48%
ROE -9.5%
ROIC N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

RXST has a Gross Margin of 71.87%. This is amongst the best in the industry. RXST outperforms 82.01% of its industry peers.
RXST's Gross Margin has improved in the last couple of years.
RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
RXST has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RXST has been increased compared to 5 years ago.
Compared to 1 year ago, RXST has an improved debt to assets ratio.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 9.85 indicates that RXST is not in any danger for bankruptcy at the moment.
The Altman-Z score of RXST (9.85) is better than 90.48% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
RXST has a better Debt to Equity ratio (0.00) than 69.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.85
ROIC/WACCN/A
WACC9.12%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 12.68 indicates that RXST has no problem at all paying its short term obligations.
RXST has a Current ratio of 12.68. This is amongst the best in the industry. RXST outperforms 96.83% of its industry peers.
RXST has a Quick Ratio of 11.65. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
RXST has a better Quick ratio (11.65) than 96.30% of its industry peers.
Industry RankSector Rank
Current Ratio 12.68
Quick Ratio 11.65
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.63% over the past year.
Looking at the last year, RXST shows a very strong growth in Revenue. The Revenue has grown by 46.69%.
Measured over the past years, RXST shows a very strong growth in Revenue. The Revenue has been growing by 128.63% on average per year.
EPS 1Y (TTM)44.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)46.69%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%28.41%

3.2 Future

RXST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.40% yearly.
Based on estimates for the next years, RXST will show a very strong growth in Revenue. The Revenue will grow by 20.29% on average per year.
EPS Next Y5.87%
EPS Next 2Y12.59%
EPS Next 3Y21.4%
EPS Next 5YN/A
Revenue Next Year19.8%
Revenue Next 2Y19.19%
Revenue Next 3Y20.03%
Revenue Next 5Y20.29%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as RXST's earnings are expected to grow with 21.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.59%
EPS Next 3Y21.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RXST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (5/22/2025, 10:10:05 AM)

15.8

-0.21 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners91.05%
Inst Owner Change4.48%
Ins Owners5.07%
Ins Owner Change-0.23%
Market Cap641.80M
Analysts75.29
Price Target25.6 (62.03%)
Short Float %11.14%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.14%
Min EPS beat(2)9.22%
Max EPS beat(2)11.05%
EPS beat(4)4
Avg EPS beat(4)21.58%
Min EPS beat(4)9.22%
Max EPS beat(4)36.3%
EPS beat(8)8
Avg EPS beat(8)21.55%
EPS beat(12)12
Avg EPS beat(12)20.96%
EPS beat(16)15
Avg EPS beat(16)18.28%
Revenue beat(2)0
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)-2.21%
Revenue beat(4)1
Avg Revenue beat(4)-0.01%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)5.95%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)3.54%
Revenue beat(16)12
Avg Revenue beat(16)4.82%
PT rev (1m)-40.4%
PT rev (3m)-51.82%
EPS NQ rev (1m)-2.71%
EPS NQ rev (3m)-71.58%
EPS NY rev (1m)-0.78%
EPS NY rev (3m)-47.91%
Revenue NQ rev (1m)-5.05%
Revenue NQ rev (3m)-14.45%
Revenue NY rev (1m)-1.68%
Revenue NY rev (3m)-11.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.33
P/FCF N/A
P/OCF N/A
P/B 2.3
P/tB 2.3
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS3.65
BVpS6.88
TBVpS6.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.48%
ROE -9.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.87%
FCFM N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.83%
Cap/Sales 2.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.68
Quick Ratio 11.65
Altman-Z 9.85
F-Score5
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)107.67%
Cap/Depr(5y)87%
Cap/Sales(3y)4.72%
Cap/Sales(5y)8.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y5.87%
EPS Next 2Y12.59%
EPS Next 3Y21.4%
EPS Next 5YN/A
Revenue 1Y (TTM)46.69%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%28.41%
Revenue Next Year19.8%
Revenue Next 2Y19.19%
Revenue Next 3Y20.03%
Revenue Next 5Y20.29%
EBIT growth 1Y22.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.6%
EBIT Next 3Y35.21%
EBIT Next 5YN/A
FCF growth 1Y68.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.27%
OCF growth 3YN/A
OCF growth 5YN/A